ANI Pharmaceuticals’ Veregen, a topical ointment derived from green tea extract (catechins), has been implemented by Shanghai Ruijin Hospital’s Hainan subsidiary. Marking a significant step for the botanical drug in China, Veregen is the first such drug approved by the US FDA since 1962 and is already in use across more than 20 countries in Europe and Taiwan, in addition to the United States .
Indicated for the treatment of condyloma acuminatum (CA), which are anogenital warts associated with human papillomavirus (HPV), Veregen was included in China’s latest clinical guidelines for this indication in 2021 . The drug has demonstrated its effectiveness in treating these warts and is part of a growing trend of adopting botanical drugs in modern medicine.
Veregen is applied topically three times a day and is used until complete clearance of the warts or up to 16 weeks, whichever comes first. The treatment has been well-tolerated in clinical trials, with common side effects including local skin reactions such as erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and rash vesicular .
This adoption by a major hospital in China underscores the global reach and potential impact of Veregen. As the drug continues to be integrated into the healthcare systems of various countries, it highlights the importance of botanical treatments in addressing specific medical conditions and the ongoing interest in herbal medicine’s role in modern healthcare solutions.- Flcube.com
